Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
39
CLVLY Quote, Financials, Valuation and Earnings
Last price:
$8.45
Seasonality move
:
1.87%
Day range:
$8.75 - $8.75
52-week range:
$6.00 - $9.00
Dividend yield:
0.37%
P/E ratio:
18.90x
P/S ratio:
7.20x
P/B ratio:
2.88x
Volume:
--
Avg. volume:
1.4K
1-year change:
14.23%
Market cap:
$439.3M
Revenue:
$61.5M
EPS (TTM):
$0.47
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Clinuvel Pharmaceuticals Ltd. has -- downside to fair value with a price target of -- per share.
CLVLY vs. S&P 500
-
Over the past 5 trading days, Clinuvel Pharmaceuticals Ltd. has overperformed the S&P 500 by 4.7% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Clinuvel Pharmaceuticals Ltd. does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Clinuvel Pharmaceuticals Ltd. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Clinuvel Pharmaceuticals Ltd. reported revenues of --.
Earnings Growth
-
Clinuvel Pharmaceuticals Ltd. has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Clinuvel Pharmaceuticals Ltd. reported earnings per share of --.
Enterprise value:
266.9M
EV / Invested capital:
--
Price / LTM sales:
7.20x
EV / EBIT:
6.54x
EV / Revenue:
4.44x
PEG ratio (5yr expected):
1.15x
EV / Free cash flow:
--
Price / Operating cash flow:
17.03x
Enterprise value / EBITDA:
6.42x
Gross Profit (TTM):
$40.2M
Return On Assets:
17.14%
Net Income Margin (TTM):
38.09%
Return On Equity:
19.45%
Return On Invested Capital:
19.39%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2011-12-31 | 2012-12-31 | 2013-12-31 | 2012-12-31 | 2013-12-31 | |
| Income Statement | ||||||
| Revenue | $952.6K | $1.3M | $1.6M | -- | -- | |
| Gross Profit | $952.6K | $701.1K | $1M | -- | -- | |
| Operating Income | -$14M | -$9.1M | -$6.6M | -$5.7M | -$3.8M | |
| EBITDA | -- | -- | -- | -$5.7M | -$3.8M | |
| Diluted EPS | -$0.44 | -$0.25 | -$0.15 | -- | -- | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $77.3M | $96.7M | $125.5M | $148.4M | -- | |
| Total Assets | $81.6M | $99M | $128.2M | $154.5M | -- | |
| Current Liabilities | $6.5M | $9.4M | $16.9M | $16.9M | -- | |
| Total Liabilities | $7.4M | $12.7M | $19.3M | $18.8M | -- | |
| Total Equity | $74.2M | $86.4M | $109M | $135.7M | -- | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2011-12-31 | 2012-12-31 | 2013-12-31 | 2012-12-31 | 2013-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$11.6M | -$7.4M | -$6.5M | -$3.1M | -$2.5M | |
| Cash From Investing | $3.3M | $2.7M | $171.3K | $269.1K | -$970 | |
| Cash From Financing | -- | $5.8M | $6.5M | -$95.2K | -- | |
| Free Cash Flow | -$11.6M | -$7.4M | -$6.5M | -$3.1M | -$2.5M | |
CLVLY
Sector
Market Cap
$439.3M
$28M
Price % of 52-Week High
97.22%
51.03%
Dividend Yield
0.37%
0%
Shareholder Yield
0.55%
-1.54%
1-Year Price Total Return
14.23%
-17.48%
Beta (5-Year)
1.130
0.518
Dividend yield:
0.37%
Annualized payout:
$0.03
Payout ratio:
-6.81%
Growth streak:
3 years
Technicals
8-day SMA
Buy
Level
$8.30
200-day SMA
Buy
Level
$7.41
Bollinger Bands (100)
Buy
Level
7.25 - 8.17
Chaikin Money Flow
Buy
Level
1.7M
20-day SMA
Buy
Level
$8.04
Relative Strength Index (RSI14)
Buy
Level
72.86
ADX Line
Buy
Level
19.2
Williams %R
Sell
Level
0
50-day SMA
Buy
Level
$7.64
MACD (12, 26)
Buy
Level
0.27
25-day Aroon Oscillator
Buy
Level
84
On Balance Volume
Sell
Level
-215.5K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (12.0179)
Buy
CA Score
(Annual)
Level (2.1439)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-5.5146)
Buy
Piotroski F Score
(Annual)
Level (7)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The firm engages in the development of SCENESSE, its proprietary photoprotective drug. It also offers drugs for the treatment of various skin disorders. The company was founded by Robert Thomas Dorr on December 14, 1999 and is headquartered in Melbourne, Australia.
Stock Forecast FAQ
In the current month, CLVLY has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CLVLY average analyst price target in the past 3 months is --.
-
Where Will Clinuvel Pharmaceuticals Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Clinuvel Pharmaceuticals Ltd. share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Clinuvel Pharmaceuticals Ltd.?
Analysts are divided on their view about Clinuvel Pharmaceuticals Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Clinuvel Pharmaceuticals Ltd. is a Sell and believe this share price will rise from its current level to --.
-
What Is Clinuvel Pharmaceuticals Ltd.'s Price Target?
The price target for Clinuvel Pharmaceuticals Ltd. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CLVLY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Clinuvel Pharmaceuticals Ltd. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of CLVLY?
You can purchase shares of Clinuvel Pharmaceuticals Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Clinuvel Pharmaceuticals Ltd. shares.
-
What Is The Clinuvel Pharmaceuticals Ltd. Share Price Today?
Clinuvel Pharmaceuticals Ltd. was last trading at $8.45 per share. This represents the most recent stock quote for Clinuvel Pharmaceuticals Ltd.. Yesterday, Clinuvel Pharmaceuticals Ltd. closed at $8.75 per share.
-
How To Buy Clinuvel Pharmaceuticals Ltd. Stock Online?
In order to purchase Clinuvel Pharmaceuticals Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get CLVLY Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CLVLY
Sector
P/E ratio
18.90x
23.89x
PEG ratio
1.15x
-0.01x
P/B ratio
2.88x
1.82x
Price / LTM sales
7.20x
1.60x
Growth Metrics
CLVLY
Sector
Revenue growth
--
4.62%
Earnings growth
--
10.88%
Revenue (5-year growth)
23.03%
6.5%
Earnings forecast
--
-$0.21
Profitability
CLVLY
Sector
Profitability FY 2025
$40.5M
$3.5M
Return on invested capital
19.39%
-31.77%
Return on assets
17.14%
-27.96%
Return on equity
19.45%
-37.63%
Earnings Date
Last Earnings Date
Aug
28
Next Earnings Date
Feb
24
Estimated Next Earnings Date
Nov
27
Balance Sheet
CLVLY
Sector
Total cash
$123.3M
$26.3M
Short term investments
--
$25.7M
Total assets
$178.7M
$78M
Long term debt
--
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
